Radius Health Inc (RDUS) was Reiterated by H.C. Wainwright to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 71 from a previous price target of $55 . H.C. Wainwright advised their investors in a research report released on Sep 21, 2016.
Many Wall Street Analysts have commented on Radius Health Inc. Maxim Group Downgraded Radius Health Inc on Aug 4, 2016 to ” Sell”, Price Target of the shares are set at $24.
On the company’s financial health, Radius Health Inc reported $-1.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.94.During the same quarter in the previous year, the company posted $-0.61 EPS.
Radius Health Inc opened for trading at $55.63 and hit $57.2 on the upside on Tuesday, eventually ending the session at $56.73, with a gain of 2.94% or 1.62 points. The heightened volatility saw the trading volume jump to 10,93,675 shares. Company has a market cap of $2,444 M.
In a different news, on Jan 27, 2016, Lorraine A. Fitzpatrick (Chief Medical Officer) purchased 200 shares at $49.28 per share price. According to the SEC, on Nov 25, 2015, Robert Ward (President & CEO) sold 25,000 shares at $62.76 per share price. On Nov 13, 2015, Gary Hattersley (Chief Scientific Officer) sold 5,683 shares at $75.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Radius Health Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058) a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901 a selective estrogen receptor down regulator/degrader (SERD) and RAD140 a nonsteroidal selective androgen receptor modulator (SARM) for the treatment of breast cancer.